Advances in dual-targeted therapy for HER2-positive breast cancer based on trastu-zumab / 中国肿瘤临床

Human epidermal growth factor receptor (HER)-2-positive breast cancer is a type of highly invasive breast cancer with a high recurrence rate. Although the single-targeted treatment for HER-2 prolongs survival, patients still develop recurrence and metas-tasis. The mechanisms of dual-targeted therapies are non-overlapping and have synergistic effects, which further improves the survival of patients. Based on trastuzumab, this article reviews the current status and progression indual-targeted therapeutic regimens con-taining anti-HER-2.